Lucid Diagnostics (NASDAQ:LUCD – Get Rating) is one of 217 public companies in the “Surgical & medical instruments” industry, but how does it compare to its peers? We will compare Lucid Diagnostics to related companies based on the strength of its analyst recommendations, valuation, risk, institutional ownership, profitability, earnings and dividends.
Valuation & Earnings
This table compares Lucid Diagnostics and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Lucid Diagnostics||$500,000.00||-$28.08 million||-1.18|
|Lucid Diagnostics Competitors||$1.15 billion||$85.96 million||-442.31|
Lucid Diagnostics’ peers have higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
|Net Margins||Return on Equity||Return on Assets|
|Lucid Diagnostics Competitors||-1,564.94%||-63.93%||-22.85%|
Insider & Institutional Ownership
6.5% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 48.1% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 5.3% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 14.2% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings for Lucid Diagnostics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Lucid Diagnostics Competitors||693||3124||7318||166||2.62|
Lucid Diagnostics currently has a consensus price target of $10.54, suggesting a potential upside of 469.82%. As a group, “Surgical & medical instruments” companies have a potential upside of 35.25%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Lucid Diagnostics is more favorable than its peers.
Lucid Diagnostics peers beat Lucid Diagnostics on 7 of the 12 factors compared.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.